Fermenta Biotech's Financial Surge: A Year of Growth and Innovation
Fermenta Biotech Limited announced a significant financial turnaround for FY25, with revenue up by 57% to INR 427.0 crore and a remarkable EBITDA boost to INR 83.3 crore from a previous loss. The company reported strong growth in human and animal nutrition sectors and launched innovative plant-based Vitamin D3 products.

- Country:
- India
Fermenta Biotech Limited, a leading Indian company, has reported substantial financial growth for the fiscal year ending March 31, 2025. The company's consolidated revenue (excluding real estate) rose by 57% to INR 427.0 crore, while EBITDA surged to INR 83.3 crore, marking a significant turnaround from a prior loss.
Key financial highlights reveal an impressive recovery with human nutrition volume growing by 48% and animal nutrition by 24% over the previous year. Fermenta introduced its innovative plant-based Vitamin D3 products and accomplished successful validation batches, leading to collaborations with global customers and regulatory bodies.
Fueled by strategic expansions and technological advancements, such as Vitadee Green™, Fermenta's robust performance has solidified its position and laid a strong foundation for future growth. The company is poised to capitalize on emerging opportunities in the global nutritional wellness sector.
(With inputs from agencies.)
ALSO READ
Russia's Oil and Gas Revenue: A Deepening Crisis
States Advocate for Equal Tax Revenue Share: Plea to Finance Commission
Apollo Green Energy Sees Surge in Profits and Revenue
Revenue Inspector Caught in Bribery Scandal in Hyderabad
YS Jagan Mohan Reddy Exposes Andhra Pradesh's GST Revenue 'Distress'